PTEN and melanoma: The combination of BrafV600E together with silencing of Pten occurs in ~20% of melanoma patients (18) and, in the mouse model, leads to the development of primary melanoma with 100% penetrance, short latency, and metastasis to lymph nodes (LNs) (15).